CJC-1295 dosage in the human studies

Amounts administered to volunteers

In Teichman’s healthy-adult studies, the reported single subcutaneous amounts were 30 or 60 micrograms per kilogram. Subcutaneous means beneath the skin. The researchers measured the peptide’s persistence and the resulting GH and IGF-1 changes.

The Ionescu and Frohman pulse study gave healthy men a single 60 or 90 micrograms per kilogram administration. Its notable findings a week later concerned basal GH, mean GH, IGF-1 and the continuing pulse pattern. The units are weight-based: an amount per kilogram of the participant’s body weight.

I’m comfortable calling these experimental amounts. Giving them the authority of a prescription would require evidence that the experiments did not produce. The published work has established no human treatment dose proved both safe and effective.

Form names and combinations

The long-acting form in the human CJC-1295 studies carried DAC. Its 5.8-8.1-day estimated half-life differs sharply from the short action associated with Modified GRF 1-29, often called no DAC. The form comparison explains that chemical distinction.

Online protocols often blur these names and also discuss the CJC-1295/ipamorelin pairing. Such protocols lack the controlled human treatment trials needed to validate a dose. There is no established human combination dose. A precise-looking online amount can still have an uncertain clinical basis.

The temptation is to make duration do the work of an efficacy trial: establish how long a molecule persists, then infer how often it ought to be given. I reject that shortcut. A useful treatment amount requires a measured benefit and an acceptable account of harm in the people being treated.

Route and laboratory handling

The early human studies administered CJC-1295 beneath the skin. The research record describes dried peptide reconstituted with bacteriostatic water and kept refrigerated; oral availability is negligible. Those details document the experimental material and route rather than establish a method for home preparation.

The missing evidence remains clinical. CJC-1295 has no approval for human use, and the discontinued Phase 2 patient trial never supplied an approved treatment regimen. For an individual health decision, a medical professional needs the person’s history as well as reliable treatment evidence. This page can supply the published study context only.